https://www.prnewswire.co.uk/news-releases/congruence-therapeutics-announces-oral-presentation-on-cgx-195-a-novel-small-molecule-aat-corrector-at-the-ers-alpha-1-antitrypsin-aat-conference-2026-302918168.html

https://www.prnewswire.com/news-releases/congruence-announces-participation-at-the-2026-bloom-burton--co-healthcare-investor-conference-302747214.html

https://www.prnewswire.com/news-releases/congruence-announces-participation-in-the-25th-annual-needham-virtual-healthcare-conference-302738712.html?tc=eml_cleartime

https://www.prnewswire.com/news-releases/congruence-announces-39-5m-financing-to-advance-portfolio-of-small-molecule-correctors-into-the-clinic-302718764.html?tc=eml_cleartime

https://www.prnewswire.com/news-releases/congruence-announces-first-dosing-in-phase-11b-clinical-trial-of-cgx-926-a-first-in-class-oral-mc4r-corrector-for-genetic-obesity-302718759.html?tc=eml_cleartime

https://www.prnewswire.com/news-releases/congruence-and-ono-pharma-expand-multi-target-research-partnership-with-the-addition-of-two-new-programs-302701525.html

https://www.prnewswire.com/news-releases/congruence-therapeutics-to-present-preclinical-characterization-of-its-mc4r-corrector-development-candidate-cgx-926-for-genetic-obesity-at-obesityweek-2025-302607289.html

https://www.prnewswire.com/news-releases/congruence-therapeutics-earns-fierce-15-distinction-for-2025-302562951.html

https://www.prnewswire.com/news-releases/congruence-therapeutics-announces-participation-in-barclays-biotech-1x1-private-company-symposium-302212895.html?tc=eml_cleartime

https://www.prnewswire.com/news-releases/congruence-therapeutics-announces-participation-in-barclays-biotech-1x1-private-company-symposium-302212895.html?tc=eml_cleartime